Figure 3.

Effect of anti-CD55 and anti-CD59 on trastuzumab-induced CDC in SK-BR-3 and BT474 cells. Lysis rates of (A) SK-BR-3 and (B) BT474 cells following pre-incubation with 50 µg/ml trastuzumab and each mAb (anti-CD55, anti-CD59, anti-CD55 + anti-CD59) (10 µg/ml) for 10 min at room temperature, then subsequent addition of 50% NHS and incubation for 1 h at 37°C. *P<0.05 compared with trastuzumab, anti-CD55 and anti-CD59 alone groups. ^#P<0.05 compared with the T + anti-CD55 and T + anti-CD59 groups. T, trastuzumab; CDC, complement-dependent cytotoxicity; CD55, complement decay-accelerating factor; CD59, CD59 glycoprotein precursor.